Cargando…

Retracted: Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma

Detalles Bibliográficos
Autor principal: Markers, Disease
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307472/
https://www.ncbi.nlm.nih.gov/pubmed/37387763
http://dx.doi.org/10.1155/2023/9826032
_version_ 1785066055532544000
author Markers, Disease
author_facet Markers, Disease
author_sort Markers, Disease
collection PubMed
description
format Online
Article
Text
id pubmed-10307472
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-103074722023-06-29 Retracted: Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma Markers, Disease Dis Markers Retraction Hindawi 2023-06-21 /pmc/articles/PMC10307472/ /pubmed/37387763 http://dx.doi.org/10.1155/2023/9826032 Text en Copyright © 2023 Disease Markers. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Retraction
Markers, Disease
Retracted: Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma
title Retracted: Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma
title_full Retracted: Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma
title_fullStr Retracted: Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma
title_full_unstemmed Retracted: Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma
title_short Retracted: Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma
title_sort retracted: clinical application of anlotinib combined with docetaxel: safe and effective treatment for lung carcinoma
topic Retraction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307472/
https://www.ncbi.nlm.nih.gov/pubmed/37387763
http://dx.doi.org/10.1155/2023/9826032
work_keys_str_mv AT markersdisease retractedclinicalapplicationofanlotinibcombinedwithdocetaxelsafeandeffectivetreatmentforlungcarcinoma